Kennametal Sees Q3 Revenue $520M-$540M Vs $510.46M Est

Outlook The Company's expectations for the third quarter of fiscal 2023 and the full year, which remain largely unchanged, are as follows: Quarterly Outlook: • Sales

Outlook

The Company’s expectations for the third quarter of fiscal 2023 and the full year, which remain largely unchanged, are as follows:

Quarterly Outlook:

Sales expected to be $520 – $540 million; includes a headwind of approximately $20 million from USD strength compared to the third quarter of fiscal 2022 and approximately 7 percent of price realization

Adjusted operating income expected to be at least $40 million:

 

Pricing is expected to substantially cover raw material costs of $23 million, higher wages and general inflation compared to the prior year quarter

 

USD strength is expected to be a headwind of approximately $4 million compared to the prior year quarter

 

Under-absorption and price/raw effects expected to improve sequentially

Total
0
Shares
Related Posts
Read More

Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss

Cannara Biotech Inc. announced on Monday its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended Feb. 29, 2024. The company reported a 68% year-over-year increase in revenues for the first half of fiscal 2024, a metrics CFO Nicholas Sosiak called "a testament to our growing influence in the Quebec, Ontario, Alberta, and BC markets." "Our proactive steps towards streamlining assets align with our ambition to fortify our financial foundation as we relentlessly stay focused on gaining market share and becoming the leader in Canada, the second-largest cannabis market in the world," Sosiak said. "As for our long-term vision, we do see our future extend beyond our borders where Cannara is a globally recognized brand synonymous with excellence and value in cannabis."

LOVE